Investigational Drug Details
| Drug ID: | D256 |
| Drug Name: | Oltipraz |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | DB12539 |
| DrugBank Description: | Oltipraz has been used in trials studying the treatment and prevention of Lung Cancer, Liver Fibrosis, Liver Cirrhosis, and Non-alcoholic Fatty Liver Disease. |
| PubChem ID: | 47318 |
| CasNo: | 64224-21-1 |
| Repositioning for NAFLD: | No |
| SMILES: | Cc1c(ssc1=S)c1cnccn1 |
| Structure: |
|
| InChiKey: | CKNAQFVBEHDJQV-UHFFFAOYSA-N |
| Molecular Weight: | 226.351 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | Anticancer agent; antiviral |
| Clinical Trial Progress: | Phase 3 on-going (NCT04142749) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0027 | NCT01373554 | Phase 2 | Completed | No Results Available | May 2011 | December 10, 2013 | Details |
| L0055 | NCT04142749 | Phase 3 | Recruiting | No Results Available | November 15, 2019 | August 21, 2020 | Details |
| L0118 | NCT02068339 | Phase 3 | Completed | No Results Available | February 2014 | March 30, 2016 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A09807 | 31602953 | Zhongguo Zhong Yao Za Zhi | [Mechanism of Calculus Bovis Sativus in inhibiting hepatocyte lipid deposition based on serum pharmacology]. | Details |
| A16717 | 28225186 | Aliment Pharmacol Ther | Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease. | Details |
| A23659 | 23592516 | Mol Pharmacol | Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. | Details |
| A27390 | 18488193 | Arch Toxicol | Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. | Details |
| A44441 | 28621080 | Aliment Pharmacol Ther | Letter: the efficacy of oltipraz in patients with non-alcoholic fatty liver disease has not been confirmed-authors' reply. | Details |
| A44442 | 28621072 | Aliment Pharmacol Ther | Letter: the efficacy of oltipraz in patients with non-alcoholic fatty liver disease has not been confirmed. | Details |